| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Innovation1 Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.022 |
| 52 Week High | US$1.20 |
| 52 Week Low | US$0.015 |
| Beta | 4.63 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -90.41% |
| 3 Year Change | -99.02% |
| 5 Year Change | -99.79% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| IVBT | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -2.2% | -3.7% |
| 1Y | -90.4% | 11.6% | 20.5% |
Return vs Industry: IVBT underperformed the US Pharmaceuticals industry which returned 16.6% over the past year.
Return vs Market: IVBT underperformed the US Market which returned 25.9% over the past year.
Price Volatility
| IVBT volatility | |
|---|---|
| IVBT Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IVBT has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IVBT's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 1 | Rick Pierce | www.innovation1bio.com |
Innovation1 Biotech Inc., does not have significant operations. Previously, it was focused on the development of modified schedule 1 molecules of botanical origin in the United States. The company was founded in 2014 and is based in Somerville, Massachusetts.
Innovation1 Biotech Inc. Fundamentals Summary
| IVBT fundamental statistics | |
|---|---|
| Market cap | US$494.35k |
| Earnings (TTM) | -US$14.08m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs IVBT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IVBT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$14.08m |
| Earnings | -US$14.08m |
Last Reported Earnings
Aug 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.63 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -6.7% |
How did IVBT perform over the long term?
See historical performance and comparison